# US 2008/0306003 A1 · Novel Compositions and Methods for Promoting, Inhibiting and Detecting Protein Entry Into Cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306003 A1
- Document ID: US20080306003A1
- Status: Published application
- Kind: A1
- Application number: 12/065,066
- Filed: 2006-08-30
- Published: 2008-12-11
- Earliest claimed: 2005-08-30
- Assignees: Boston Medical Center Corporation
- Inventors: John R. Murphy; Ryan Ratts
- Web page: https://patentgrep.com/patent/US20080306003A1

## CPC

- G01N 33/5076: {involving cell organelles, e.g. Golgi complex, endoplasmic reticulum}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- C07K 14/34: from Corynebacterium (G)
- C07K 14/55: IL-2
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/5035: {on sub-cellular localization}
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- G01N 2510/00: Detection of programmed cell death, i.e. apoptosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention features methods for identifying compounds that inhibit cell death, and methods for identifying compounds that promote cell death, by blocking or accelerating, respectively, the translocation of the catalytic domain of toxins or transcription factors through the endosomal membrane into the cytosol of a cell. Also featured are methods for inhibiting cell death that include the administration of polypeptides that include a toxin consensus sequence recognized by one or more components of the cytosolic translocation factor complex.

## Claims

### Claim 1

A polypeptide comprising the sequence of formula I,
AA215-AA216-AA217-AA218-AA219-AA220-AA221-AA222-AA223-AA224 (I),
wherein AA215 is Thr, Ser, Gly, or Leu; AA216 is Glu, Arg, Gln, or Lys; AA217 is Lys, Ile, Glu, or Val; AA218 is Glu or Asp; AA219 is Lys, Glu, His, Leu, Arg, Asn, or Ser; AA220 is Phe, Leu, or Ile; AA221 is Lys or Arg; AA222 is Glu, Asn, Asp, or Lys; AA223 is Lys, His, Ser, Ile, or Asn; and AA224 is Gly, Leu, Val, Met, or Ile.

### Claim 2 (depends on 1)

The polypeptide of claim 1, wherein said polypeptide further comprises one or more KXKXX sequences.

### Claim 3 (depends on 2)

The polypeptide of claim 2, wherein said polypeptide comprises three KXKXX sequences.

### Claim 4 (depends on 1)

The polypeptide of claim 1, wherein said polypeptide comprises the sequence set forth in any one of SEQ ID NOs. 1-27.

### Claim 5 (depends on 4)

The polypeptide of claim 4, wherein said polypeptide comprises the sequence set forth in SEQ ID NO: 2.

### Claim 6 (depends on 2)

The polypeptide of claim 2, wherein said polypeptide comprises the sequence set forth in SEQ ID NO. 8.

### Claim 7 (depends on 1)

The polypeptide of claim 1, wherein said polypeptide is further reacted with a monoclonal antibody, or fragment thereof.

### Claim 8 (depends on 1)

Use of a polypeptide of claim 1 in the manufacture of a medicament for inhibiting cell death in a mammal.

### Claim 9 (depends on 8)

The use of claim 8, wherein said polypeptide inhibits the translocation of a viral or bacterial toxin from the lumen of an endosome to the cytosol of a cell.

### Claim 10 (depends on 9)

The use of claim 9, wherein said toxin is an AB toxin.

### Claim 11 (depends on 9)

The use of claim 9, wherein said toxin is selected from the group consisting of: Diphtheria toxin, Botulinum toxin, Anthrax toxin LF, and Anthrax toxin EF.

### Claim 12 (depends on 8)

The use of claim 8, wherein said polypeptide inhibits the translocation of a viral or retroviral transcription factor.

### Claim 13 (depends on 12)

The use of claim 12, wherein said factor is human immunodeficiency virus reverse transcriptase.

### Claim 14 (depends on 12)

The use of claim 12, wherein said factor is Tat.

### Claim 15 (depends on 8)

The use of claim 8, wherein said mammal is a human.

### Claim 16 (depends on 8)

The use of claim 8, wherein said medicament further comprises a pharmaceutically acceptable vehicle.

### Claim 17 (depends on 1)

A nucleic acid sequence encoding the polypeptide sequence of claim 1.

### Claim 18 (depends on 17)

The nucleic acid sequence of claim 17, wherein said nucleic acid sequence encodes the polypeptide sequence set forth in SEQ ID NO. 2.

### Claim 19 (depends on 17)

The nucleic acid sequence of claim 17, wherein said nucleic acid sequence is operably linked to an inducible promoter.

### Claim 20 (depends on 17)

Use of a nucleic acid of claim 17, in the manufacture of a medicament for inhibiting cell death in a mammal.

### Claim 21 (depends on 20)

The use of claim 20, wherein said mammal is a human.

### Claim 22 (depends on 20)

The use of claim 20, wherein said medicament further comprises a pharmaceutically acceptable vehicle.

### Claim 23

A method of identifying a compound that inhibits cell death in a mammal comprising the following steps:
a) isolating, from a cell, intact endosomes comprising a toxin, wherein the endosomes are maintained in a neutral or basic pH;
b) placing said endosomes in a cytosolic buffer;
c) contacting said endosomes with one or more of α-COP, β-COP, β′-COP, γ-COP, δ-COP, ε-COP, ζ-COP, HSP-90, or TrR-1;
d) contacting said endosomes with said compound;
e) acidifying said endosomes; and
f) measuring translocation of said toxin across a membrane of said endosomes, wherein a decreased level of said translocation relative to that observed in the absence of said compound indicates that said compound inhibits said cell death.

### Claim 24 (depends on 23)

The method of claim 23, wherein said endosomes are early endosomes.

### Claim 25 (depends on 23)

The method of claim 23, wherein said toxin is selected from Diphtheria toxin, Botulinum toxin, Anthrax toxin LF, or Anthrax toxin EF.

### Claim 26 (depends on 23)

The method of claim 23, wherein said toxin is Diptheria toxin.

### Claim 27 (depends on 23)

The method of claim 23, wherein said toxin is a fusion protein.

### Claim 28 (depends on 27)

The method of claim 27, wherein said fusion protein comprises Diptheria toxin and IL-2.

### Claim 29 (depends on 28)

The method of claim 28, wherein said fusion protein is DAB389IL-2.

### Claim 30 (depends on 23)

The method of claim 23, wherein step c) comprises contacting said endosomes with γ-COP.

### Claim 31 (depends on 25)

The method of claim 25, wherein step c) comprises contacting said endosomes with α-COP, β-COP, β′-COP, γ-COP, δ-COP, ε-COP, ζ-COP, HSP-90, and TrR-1.

### Claim 32 (depends on 23)

The method of claim 23, wherein measuring said translocation comprises measuring the ADP-ribosylation of elongation factor-2.

### Claim 33

A method of identifying a compound that promotes cell death in a mammal comprising the following steps:
a) isolating, from a cell, intact endosomes comprising a toxin, wherein the endosomes are maintained in a neutral or basic pH;
b) placing said endosomes in a cytosolic buffer;
c) contacting said endosomes with one or more of α-COP, β-COP, β′-COP, γ-COP, δ-COP, ε-COP, ζ-COP, HSP-90, or TrR-1;
c) contacting said endosomes with said compound;
d) acidifying said endosomes; and
e) measuring translocation of said toxin, wherein an increased level of said translocation relative to that observed in the absence of said compound indicates that said compound promotes said cell death.

### Claim 34 (depends on 33)

The method of claim 33, wherein said endosomes are early endosomes.

### Claim 35 (depends on 33)

The method of claim 33, wherein said toxin is selected from Diphtheria toxin, Botulinum toxin, Anthrax toxin LF, or Anthrax toxin EF.

### Claim 36 (depends on 33)

The method of claim 33, wherein said toxin is Diptheria toxin.

### Claim 37 (depends on 33)

The method of claim 33, wherein said toxin is a fusion protein.

### Claim 38 (depends on 37)

The method of claim 37, wherein said fusion protein comprises Diptheria toxin and IL-2.

### Claim 39 (depends on 38)

The method of claim 38, wherein said fusion protein is DAB389IL-2.

### Claim 40 (depends on 33)

The method of claim 33, wherein step c) comprises contacting said endosomes with γ-COP.

### Claim 41 (depends on 35)

The method of claim 35, wherein step c) comprises contacting said endosomes with α-COP, β-COP, β′-COP, γ-COP, δ-COP, ε-COP, ζ-COP, HSP-90, and TrR-1.

### Claim 42 (depends on 33)

The method of claim 33, wherein measuring said translocation comprises measuring the ADP-ribosylation of elongation factor-2.

### Claim 43

A method of inhibiting cell death in a mammal comprising administering to said mammal a polypeptide of formula I,
AA215-AA216-AA217-AA218-AA219-AA220-AA221-AA222-AA223-AA224 (I),
wherein AA215 is Thr, Ser, Gly, or Leu; AA216 is Glu, Arg, Gln, or Lys; AA217 is Lys, Ile, Glu, or Val; AA218 is Glu or Asp; AA219 is Lys, Glu, His, Leu, Arg, Asn, or Ser; AA220 is Phe, Leu, or Ile; AA221 is Lys or Arg; AA222 is Glu, Asn, Asp, or Lys; AA221 is Lys, His, Ser, Ile, or Asn; and AA224 is Gly, Leu, Val, Met, or Ile;
wherein said polypeptide further comprises one or more KXKXX sequences; and
wherein said polypeptide inhibits cell death in said mammal.

### Claim 44

A method of inhibiting cell death in a mammal comprising administering to said mammal a nucleic acid sequence encoding a polypeptide having the sequence of formula I,
AA215-AA216-AA217-AA218-AA219-AA220-AA221-AA222-AA223-AA224 (I),
wherein AA215 is Thr, Ser, Gly, or Leu; AA216 is Glu, Arg, Gln, or Lys; AA217 is Lys, Ile, Glu, or Val; AA218 is Glu or Asp; AA219 is Lys, Glu, His, Leu, Arg, Asn, or Ser; AA220 is Phe, Leu, or Ile; AA221 is Lys or Arg; AA222 is Glu, Asn, Asp, or Lys; AA223 is Lys, His, Ser, Ile, or Asn; and AA224 is Gly, Leu, Val, Met, or Ile;
wherein said nucleic acid further encodes one or more KXKXX sequences; and
wherein said polypeptide inhibits cell death in said mammal.
